How Risdiplam Validated RNA as a Drug Target
Risdiplam works by binding intronic recognition element motifs (iREMs) within SMN2 pre-mRNA to modulate exon inclusion, increasing production of functional SMN protein in patients with spinal muscular atrophy (SMA). This mechanism—a small molecule that directly reprograms pre-mRNA splicing rather than silencing a protein target—established a new pharmacological category and catalyzed broad interest in RNA-targeted pharmacology across neurological disease.
A PTC Medical Corporation (PTC Therapeutics) patent describes small-molecule splicing modifier compounds operating through iREM motifs—the same mechanistic class as risdiplam—and explicitly covers SMN2 splicing modulation for SMA treatment while addressing multiple additional disease contexts, signalling a platform approach beyond SMA. The retrieved patent dataset spans active filings across splice-switching antisense oligonucleotides (ASOs), RNAi platforms, microRNA modulators, and small-molecule splicing correctors targeting TDP-43 pathology, tau (MAPT), UNC13A, STMN2, and other neurodegeneration-linked RNA species, according to PatSnap’s innovation intelligence platform.
An iREM is a structured RNA element within an intron that small-molecule splicing modifiers such as risdiplam can bind, altering the spliceosome’s recognition of adjacent exons. By binding iREMs in SMN2 pre-mRNA, risdiplam promotes inclusion of exon 7, producing functional full-length SMN protein instead of the truncated, unstable isoform.
The clinical success of risdiplam is particularly significant because it demonstrated that orally bioavailable small molecules can achieve meaningful CNS exposure and correct disease-causing splicing errors—an advantage over intrathecally delivered ASOs that has energised the search for iREM-like elements in other neurodegeneration-relevant transcripts. According to WIPO, RNA therapeutics represent one of the fastest-growing categories in pharmaceutical patent filings globally, and the neurological disease segment is a primary driver of that growth.
Risdiplam is a small-molecule splicing modifier that acts on intronic recognition element motifs (iREMs) within SMN2 pre-mRNA to modulate exon inclusion, increasing production of functional SMN protein as a treatment for spinal muscular atrophy (SMA).
The TDP-43/STMN2/UNC13A Axis: ALS/FTD’s Hottest IP Zone
TDP-43 nuclear depletion is the central event connecting most ALS cases and a significant proportion of FTD to RNA mis-processing: when TDP-43 mislocalises to the cytoplasm, cryptic exons are aberrantly included in STMN2 (stathmin-2) and UNC13A transcripts, causing loss of axonal regeneration capacity and synaptic dysfunction respectively. Multiple organisations—Roche, University of Massachusetts, Quralis Corporation, and Regeneron Pharmaceuticals—are converging on this mechanistic pathway with distinct but overlapping ASO approaches.
“The TDP-43/STMN2/UNC13A axis represents the most extensively covered mechanistic nexus in the RNA neurotherapeutics patent dataset—with filings from Roche, University of Massachusetts, Quralis, and Regeneron all converging on the same disease model.”
TDP-43 (encoded by TARDBP) is a nuclear RNA/DNA binding protein that regulates mRNA splicing, transport, and stability. A filing from the University of Massachusetts specifically addresses restoring STMN2 levels via ASOs targeting TDP-43-regulated splice sites. A Roche filing describes ASOs complementary to TDP-43 binding sites on pre-mRNA to restore RNA-binding protein function in TDP-43-depleted cells. Quralis Corporation discloses oligonucleotides with or without spacers targeting UNC13A missplicing in ALS, FTD, and AD.
Pathological mislocalization of TDP-43 to the cytoplasm—with loss of nuclear function—underlies most ALS cases and a significant proportion of FTD, causing aberrant inclusion of cryptic exons in STMN2 (stathmin-2) and failure to regulate UNC13A transcripts, resulting in loss of axonal regeneration capacity and synaptic dysfunction.
Regeneron Pharmaceuticals takes a distinct approach: filings describe TDP-43 prion-like domain (PLD) swap variants resistant to aggregation as a gene therapy modality, with anti-aggregation TDP-43 variants replacing the wild-type PLD with that of hnRNPA2B1. The University of British Columbia discloses ASO/siRNA/shRNA targeting RACK1 to inhibit TDP-43 and FUS aggregation across ALS, AD, frontotemporal lobar degeneration (FTLD), and Huntington’s disease. Drug developers and IP strategists should map freedom-to-operate carefully around splice-site-specific ASO sequences targeting STMN2 cryptic exons and UNC13A missplicing, as these filings may become foundational patents for ALS/FTD RNA therapeutics.
Map freedom-to-operate across TDP-43, STMN2, and UNC13A patent filings with PatSnap Eureka.
Explore RNA Therapeutics Patents in PatSnap Eureka →Tau (MAPT) Targeting: From Bench to Biogen’s Clinical Signal
Tau (MAPT) mRNA knockdown is the most clinically advanced RNA target in the neurodegeneration patent dataset, with Biogen’s filing explicitly referencing ISIS 814907—a MAPT-targeting ASO—for administration to human subjects with mild Alzheimer’s disease and mild cognitive impairment (MCI) due to AD. This is the clearest clinical translation signal in the retrieved dataset.
Biogen MA Inc.’s patent filing explicitly references ISIS 814907, a MAPT-targeting antisense oligonucleotide, for administration to human subjects with mild Alzheimer’s disease and mild cognitive impairment (MCI) due to AD—the only compound in the retrieved RNA neurotherapeutics patent dataset with an explicit human clinical evaluation signal.
Ionis Pharmaceuticals, F. Hoffmann-La Roche, Dicerna Pharmaceuticals, and Biogen all identify MAPT mRNA and its encoded tau protein as targets for oligonucleotide-mediated knockdown in tauopathies including AD, FTD, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), and corticobasal degeneration. Approaches include gapmer ASOs targeting MAPT mRNA for RNase H-mediated degradation, LNA-modified oligonucleotides, and lipid-conjugated RNAi oligonucleotides. Columbia University separately discloses microRNAs targeting the 3′ UTR of tau mRNA for AD and tauopathy—a distinct mechanism that operates post-transcriptionally rather than through RNase H-mediated degradation.
The Roche Indonesia filing covers tauopathies, AD, FTD, PSP, CTE, corticobasal degeneration, epilepsy, and Dravet syndrome—suggesting clinical development intent across multiple indications. The breadth of indication coverage in a single filing is consistent with a platform approach to tau ASO chemistry, as documented by organisations such as the NIH in their tau biology research programmes.
Six Modalities Competing to Reach the CNS
The RNA neurotherapeutics patent landscape is not a single-modality race: six distinct therapeutic classes are actively filing, each with different delivery chemistry, CNS penetration profiles, and target access. Activity is predominantly patent-driven, consistent with the commercial trajectory of the oligonucleotide and RNA-targeting small molecule space.
1. Small-Molecule RNA Splicing Modulators (SMSMs)
The risdiplam mechanism class, represented by the PTC Medical Corporation iREM platform. The compounds described by Formula (I) act on pre-mRNA transcripts containing iREM elements to modulate exon inclusion or exclusion, with explicit coverage of SMN2 splicing modulation for SMA and a platform approach addressing multiple disease contexts. Oral bioavailability is the key differentiator versus ASO/siRNA approaches.
2. Antisense Oligonucleotides (ASOs) — Gene Silencing and Splice-Switching
The largest modality cluster in the dataset. ASOs appear in multiple chemical formats including locked nucleic acid (LNA) gapmers, morpholino (PMO), peptide-morpholino (PPMO), 2′-MOE gapmers, and phosphorothioate backbones. Applications span tau/MAPT knockdown (Ionis, Roche, Dicerna), TDP-43 pathway rescue (Roche, University of Massachusetts), CD33 exon skipping in AD (Eisai R&D), UNC13A splice correction (Quralis), ATXN3 modulation for SCA3 (Roche Innovation Center Copenhagen), RBM3 upregulation via poison exon targeting (Freie Universität Berlin), and BDNF natural antisense suppression (Curna Inc./OPKO Curna).
3. RNA Interference (siRNA/shRNA) — CNS Delivery
Multiple filings address RNAi-based knockdown with a strong emphasis on overcoming CNS delivery barriers. Dicerna Pharmaceuticals uses lipid-conjugated RNAi oligonucleotides for neuronal distribution across hippocampus, frontal cortex, and spinal cord following single dosing. Alnylam Pharmaceuticals discloses bis-RNAi molecules (circular siRNA, sciRNA constructs) targeting two or more mRNAs simultaneously in CNS. Genzyme Corporation delivers alpha-synuclein RNAi via rAAV vectors for Parkinson’s disease and synucleinopathies. Switch Therapeutics discloses conditionally activatable siRNA complexes triggered by disease-specific endogenous RNA sequences—a logic-gated approach. Medtronic’s early platform filing covers intracranial siRNA delivery via implanted catheter for Alzheimer’s, Parkinson’s, Huntington’s, and spinocerebellar ataxias.
4. MicroRNA Modulators (miRNA mimics / antagomirs)
A substantial cluster covers miRNA targeting: Miragen Therapeutics discloses oligonucleotide inhibitors of miR-155 (11–16 nucleotides in length) for neuroinflammation and ALS, noting miR-155 upregulation in sporadic and familial ALS patient spinal cord. Academia Sinica describes sustained expression of the miR-17~92 cluster in spinal motor neurons and its downregulation preceding motor neuron loss in SOD1-G93A mice. NeuMirna Therapeutics targets miR-27b for epilepsy and CNS diseases. Seoul National University discloses miR-206 inhibition to upregulate BDNF and IGF-1 in AD models.
5. Engineered Polynucleotides / Spliceosome Recruiters
Aptar Bio, Inc. describes engineered polynucleotides containing stem-loop structures that recruit the spliceosome, combined with targeting sequences complementary to exon-intron splice junctions, incorporating 2′-modified nucleotides and phosphorothioate linkages, for treatment of neurodegenerative diseases. This represents a hybrid between ASO and RNA scaffold approaches.
6. Tricyclo-DNA (tc-DNA) Antisense Oligonucleotides
Association Institut de Myologie and University of Bern disclose tc-DNA AONs that can cross the blood-brain barrier when administered peripherally, enabling exon skipping (DMD), intronic silencer masking (SMA/SMN2), and CUG-repeat targeting (myotonic dystrophy DM1). The CNS penetration potential of tc-DNA AONs is noted as a distinct advantage versus conventional chemistries, addressing the primary engineering challenge identified across the dataset. Research standards for oligonucleotide chemistry characterisation are maintained by organisations including ISO.
The concentration of filings around lipid conjugation (Dicerna), bis-RNAi CNS formats (Alnylam), peptide-ASO conjugates (Eisai), and tc-DNA peripheral administration (Institut de Myologie) indicates that the RNA-targeting modality race in CNS will be decided substantially by delivery chemistry. Delivery platform IP should be weighted as critically as target biology in investment and partnership decisions.
Analyse CNS delivery platform patents across all six RNA therapeutic modalities in PatSnap Eureka.
Search CNS Delivery Patents in PatSnap Eureka →Emerging Directions: Logic-Gating, ADAR Editing, and Poison Exons
Beyond the established modalities, several patent signals describe approaches that represent genuine paradigm shifts in how RNA biology can be exploited therapeutically in the CNS—moving from bulk silencing toward precision cell-type and disease-state-specific RNA modulation.
Multi-target RNAi (Bis-RNAi / sciRNA): Alnylam’s bis-RNAi/sciRNA constructs targeting two or more mRNA targets simultaneously in CNS represent a move toward polypharmacology at the RNA level. This could address the multi-factorial nature of ALS and AD, where single-target approaches have shown limited efficacy.
Conditionally Activatable / Logic-Gated Oligonucleotides: Switch Therapeutics’ conditionally activatable siRNA complexes—activated by disease-specific endogenous RNA sequences—signal a next-generation approach to cell-type or disease-state selectivity in the CNS, potentially reducing off-target effects. This approach is described in filings across CN and JP jurisdictions.
ADAR-Based RNA Editing (CellREADR): Cold Spring Harbor Laboratory discloses modular RNA molecules (readrRNA/CellREADR) that use endogenous ADAR (adenosine deaminase acting on RNA) sensing to detect cell-type-specific RNAs and couple detection to effector protein translation. Application to epilepsy and neurological circuit modulation is described—an entirely distinct paradigm from classical RNA knockdown or silencing.
Cold Spring Harbor Laboratory discloses CellREADR, a modular RNA molecule approach that uses endogenous ADAR (adenosine deaminase acting on RNA) to sense cell-type-specific RNAs and couple detection to effector protein translation, with application to epilepsy and neurological circuit modulation—an entirely distinct paradigm from classical RNA knockdown.
Poison Exon-Targeting for Upregulation: RBM3 upregulation via ASO-mediated poison exon blocking (Freie Universität Berlin) extends the splice-switching principle to increasing target gene expression—relevant for neuroprotective factors that are downregulated in neurodegeneration. This mirrors the risdiplam/SMN2 logic (exon inclusion rather than exclusion) but applied to neuroprotection via RBM3.
DRG De-targeting via miRNA Binding Sites in AAV Vectors: Encoded Therapeutics and Kate Therapeutics describe miRNA binding sites (including miR-338-3p, miR-138-5p, miR-9-5p, and miR-10b-5p) in AAV vectors that detarget transgene expression from dorsal root ganglia (DRG), addressing a key safety concern in CNS gene therapy. This represents a combination of RNA biology and gene therapy vector engineering. The safety and regulatory implications of such approaches are tracked by agencies including the EMA in their advanced therapy medicinal product frameworks.
TDP-43 Anti-Aggregation Variants as Gene Therapy Payload: Regeneron’s concept of replacing wild-type TDP-43 with an anti-aggregation PLD-swap variant (hnRNPA2B1 PLD) introduces a gene therapy plus protein engineering combination potentially deliverable via ASO-mediated suppression of endogenous TDP-43 plus viral delivery of the replacement variant—a multi-modal approach that blurs the boundary between RNA therapeutics and gene therapy.
Regeneron Pharmaceuticals discloses TDP-43 prion-like domain (PLD) swap variants—replacing the wild-type PLD with that of hnRNPA2B1—as anti-aggregation gene therapy payloads for ALS and FTD, representing a combination of ASO-mediated endogenous TDP-43 suppression and viral delivery of the replacement variant.
Strategic Implications for IP and Drug Development Teams
The RNA neurotherapeutics patent landscape presents several concrete strategic considerations for IP professionals, R&D leaders, and investors operating in this space.
The TDP-43/STMN2/UNC13A axis is a high-activity IP zone requiring careful FTO analysis. Multiple filings from Roche, University of Massachusetts, Quralis, and Regeneron are converging on the same mechanistic pathway. Splice-site-specific ASO sequences targeting STMN2 cryptic exons and UNC13A missplicing may become foundational patents for ALS/FTD RNA therapeutics, and freedom-to-operate mapping should be a priority for any programme entering this space.
Small-molecule splicing modifiers remain an underexplored IP space outside SMA. The PTC iREM platform signals that the risdiplam-class mechanism may be extensible to other pre-mRNA targets. Identifying RNA structures with druggable iREM elements in MAPT, UNC13A, or FUS transcripts could define next-generation programmes with oral bioavailability advantages over ASO/siRNA approaches. According to EMA guidance on oligonucleotide therapeutics, oral delivery remains a significant unmet need in CNS RNA pharmacology.
“Academic institutions—University of Massachusetts, Columbia University, Freie Universität Berlin, University of British Columbia—are generating foundational mechanistic IP in TDP-43 biology, STMN2 restoration, miRNA-tau biology, and RBM3 upregulation, representing licensing and partnership opportunities for pharma seeking early-stage RNA target validation.”
Conditional activation and cell-type selectivity are emerging as differentiation strategies. Logic-gated siRNA (Switch Therapeutics), ADAR-based RNA sensing (Cold Spring Harbor Laboratory), and miRNA-detargeting elements in gene therapy vectors signal a shift from bulk CNS silencing toward precision cell-type and disease-state-specific RNA modulation—relevant for both efficacy and safety differentiation. Patent activity in these areas is early-stage, suggesting windows for freedom-to-operate and first-mover IP positioning.
Academic institutions are generating foundational mechanistic IP. University of Massachusetts (STMN2 restoration ASOs), Columbia University (tau-suppressing microRNAs), Penn State Research Foundation (NeuroD1-based neuronal regeneration), University of British Columbia (RACK1 knockdown for TDP-43/FUS aggregation), and Freie Universität Berlin (RBM3 poison exon targeting) represent licensing and partnership opportunities for pharma and biotech seeking early-stage RNA target validation with associated IP. The global patent landscape for RNA therapeutics in neurology is tracked comprehensively by EPO through its biotechnology patent classification system.
All modalities beyond the Biogen ISIS 814907 tau ASO appear to be at preclinical stages based on available dataset signals. No explicit clinical trial data, patient outcomes, or IND submissions are referenced beyond the Biogen ISIS 814907 case in the retrieved patent dataset—a signal that the RNA neurotherapeutics field, despite its breadth of IP activity, remains predominantly pre-clinical and that clinical translation risk remains high across most programmes.